Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Skye Bioscience, Inc. (SKYE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0710-0.0033 (-4.51%)
At close: 3:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0743
Open0.0749
BidN/A x N/A
AskN/A x N/A
Day's Range0.0670 - 0.0749
52 Week Range0.0250 - 0.2590
Volume3,995,934
Avg. Volume1,803,134
Market Cap24.851M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

    Exclusive sponsored research agreement with endocannabinoid research pioneersSAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing n

  • GlobeNewswire

    Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

    SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development. Rhea Williams, MPH, brings over 25 years of experience in drug development,

  • GlobeNewswire

    Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

    SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors. "On behalf of t

Advertisement
Advertisement